NKTR Deadline: Rosen Law Firm Urges Nektar Therapeutics (NASDAQ: NKTR) Stockholders to Contact the Firm for Information About Their RightsApril 27, 2026
Share Twitter Facebook LinkedIn Email IBM reports its highest revenue growth in years, driven by software and infrastructure performance, while setting ambitious goals for AI and hybrid cloud advancements.Read More